Indeed, the major finding that targeting the CTLA-4 pathway via antibody blockade can enhance anti-tumor responses was first demonstrated in a preclinical mouse model (12), highlighting the relevance and usefulness of murine cancer model systems. Here, CTLA4 is linked to cancer.